Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Short term Debt (2016 - 2023)

Cartesian Therapeutics (RNAC) has disclosed Short term Debt for 8 consecutive years, with $28.3 million as the latest value for Q4 2023.

  • Quarterly Short term Debt rose 233.97% to $28.3 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $28.3 million through Dec 2023, up 233.97% year-over-year, with the annual reading at $28.3 million for FY2023, 233.97% up from the prior year.
  • Short term Debt for Q4 2023 was $28.3 million at Cartesian Therapeutics, up from $10.2 million in the prior quarter.
  • The five-year high for Short term Debt was $28.3 million in Q4 2023, with the low at $460000.0 in Q1 2021.
  • Average Short term Debt over 5 years is $11.1 million, with a median of $8.5 million recorded in 2022.
  • The sharpest move saw Short term Debt tumbled 97.27% in 2021, then skyrocketed 1368.1% in 2023.
  • Over 5 years, Short term Debt stood at $18.9 million in 2019, then plummeted by 55.65% to $8.4 million in 2020, then fell by 28.9% to $6.0 million in 2021, then surged by 42.19% to $8.5 million in 2022, then skyrocketed by 233.97% to $28.3 million in 2023.
  • According to Business Quant data, Short term Debt over the past three periods came in at $28.3 million, $10.2 million, and $10.2 million for Q4 2023, Q2 2023, and Q1 2023 respectively.